A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route (Q80156066)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 November 2007

Language	Label	Description	Also known as
English	A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route	scientific article published on 09 November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Laurent Mascarell

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Laurence Van Overtvelt

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Vincent Lombardi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Alain Razafindratsita

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hélène Moussu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Stéphane Horiot

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Henri Chabre

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

David Limal

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Stéphane Moutel

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jacques Bauer

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Carlo Chiavaroli

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Philippe Moingeon

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

9 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

108-118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Desensitising vaccines: an allergist's view

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Sublingual immunotherapy for allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Efficacy and safety of sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Safety of sublingual immunotherapy in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Sublingual immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Safety of sublingual immunotherapy with a monomeric allergoid in very young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Immunotherapy: 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Oral tolerance is determined at the level of draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Preferential expression of IgG2b in nose draining cervical lymph nodes and its putative role in mucosal tolerance induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Immunologic changes associated with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

T cell activation, from atopy to asthma: more a paradox than a paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Immunomodulation during sublingual therapy in allergic children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Restoration of cytokine imbalance by immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

T regulatory cells in allergy and health: a question of allergen specificity and balance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

OM197-MP-AC induces the maturation of human dendritic cells and promotes a primary T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Synthetic triacylated lipid A derivative activates antigen presenting cells via the TLR4 pathway and promotes antigen-specific responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Treatment of established asthma in a murine model using CpG oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Immunological foundations to the quest for new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Interferon γ: a crucial role in the function of induced regulatory T cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

The adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.050

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.10.050

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18063445%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80156066&oldid=2114153862"